NPS Logo


November 4, 2009
NPS Pharmaceuticals Reports Third Quarter Results and Improved Cash Burn Guidance

October 29, 2009
NPS Pharmaceuticals to Report Third Quarter Financial Results on November 4, 2009

more news


STEPS

Now enrolling patients in a Phase 3 clinical trial evaluating GATTEX™ (teduglutide) for reducing parenteral nutrition (PN) dependence in short-bowl syndrome (SBS) patients.  To learn more click here.

REPLACE

Now enrolling patients in a Phase 3 clinical trial, known as REPLACE, evaluating NPSP558 (recombinant full-length human parathyroid hormone 1-84) for the treatment of hypoparathyroidism.  To learn more click here